An FDA advisory panel votes against recommending a new diabetes drug being developed by...
An FDA advisory panel votes against recommending a new diabetes drug being developed by AstraZeneca (AZN) and Bristol-Myers (BMY), questioning whether there's sufficient efficacy and safety data to support the drug's approval. AstraZeneca -0.7% in London.
From other sites
at Zacks.com (Mar 20, 2015)
at Zacks.com (Mar 19, 2015)
at Zacks.com (Mar 18, 2015)
at Nasdaq.com (Feb 17, 2015)
at Benzinga.com (Feb 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs